Status:
COMPLETED
Safety and Efficacy of MEM 3454 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease
Lead Sponsor:
Memory Pharmaceuticals
Conditions:
Alzheimer's Disease
Eligibility:
All Genders
50-80 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine in an 8-week treatment study if MEM 3454 is a safe and effective treatment for patients with mild to moderate Alzheimer's disease.
Detailed Description
Alzheimer's disease is the leading cause of dementia and one of the most common diseases of the aging population. It is a chronic brain disease that involves gradual memory loss, decline in the abilit...
Eligibility Criteria
Inclusion
- Diagnosis of probable or possible Alzheimer's disease
- MMSE score between 16 and 26 points
- Modified Hachinski Ischemia Score of less than or equal to 4
- Capable of performing cognitive tests and other procedures specified in protocol
Exclusion
- Head trauma associated with cognitive impairment
- Evidence of significant neurological disease other than AD, such as Parkinson's disease, multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus, CNS tumor, progressive supranuclear palsy, seizure disorder, etc.
- Received AChE inhibitor therapy (e.g., rivastigmine, tacrine or galantamine) or NDMA-receptor antagonist, memantine, within 30 days or donepezil within 40 days of randomization
- Received any investigational drug within 2 months of randomization or treatment with other nicotinic receptor agonists within 3 months of screening
Key Trial Info
Start Date :
February 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2007
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT00454870
Start Date
February 1 2007
End Date
October 1 2007
Last Update
May 6 2008
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Phoenix, Arizona, United States, 85013
2
Glendale, California, United States, 91206
3
Atlanta, Georgia, United States, 30308
4
Wichita, Kansas, United States, 67207